MeiraGTx Holdings Plc (MGTX)

Over the past six months, MeiraGTx's share price increased by 59.65% between April 7, 2025, and April 2, 2026. The company's AAV2-hAQP1 treatment received FDA Breakthrough Therapy Designation on March 26, 2026. In November 2025, MeiraGTx collaborated with Eli Lilly and Company for gene therapies, receiving an upfront payment of $75 million. In October 2024, positive data was announced from a clinical study of AAV-GAD for Parkinson's disease. MeiraGTx reported a narrower full-year 2025 loss, but also reported a Q3 FY 2025 loss reinforcing bearish narratives.

Information directly detailing demand seasonality for MeiraGTx Holdings Plc's products and services is not readily available. As a clinical-stage company, its focus is on research, development, and clinical trials rather than the commercial sale of established products.

MeiraGTx Holdings Plc (MGTX) is a clinical-stage genetic medicines company focused on developing treatments for serious diseases within the Pharmaceuticals & Biotech sector. The company is vertically integrated with a pipeline of late-stage clinical programs, focusing on ocular, neurodegenerative diseases, and xerostomia. Its pipeline includes programs such as AAV-RPE65 for RPE65-associated retinal dystrophy, AAV-GAD for Parkinson's disease, and AAV-AQP1 for radiation-induced xerostomia. The company also utilizes a riboswitch platform and is developing cell therapies for oncology, autoimmune disease, and long-term intractable pain.

MeiraGTx Holdings Plc is headquartered in New York, New York, United States. The company has a global footprint and generates a majority of its revenue from the United Kingdom.

MeiraGTx's brand reputation has been positively influenced by a "Moderate Buy" recommendation from eight brokerages and the FDA's Breakthrough Therapy Designation for its AAV2-hAQP1 treatment. The strategic collaboration with Eli Lilly and Company and positive clinical trial results for AAV-AIPL1 have also contributed to a favorable perception.

MeiraGTx Holdings Plc has 134 institutional owners and shareholders, including Sanofi, Perceptive Advisors Llc, and Johnson & Johnson. As of March 2026, institutional investors held 82.90% of the company's shares, while individual insiders held 9.70% and mutual funds held 7.82%.